We showed that the combination of KRASG12D inhibition and PI3K-AKT-mTOR pathway inhibition co-operated effectively in reducing tumor viability in vitro and in vivo, whilst other combinations were mostly additive or antagonistic. The gene discussed is MTOR; the disease is neoplasm.